Get the Stockscreener App
0.9444
33.03%
0.2345
Pre-market:
.82
-0.1244
-13.17%
Equillium Inc Stock (EQ) Latest News
Biocon, Equillium announce positive data from Phase 2 Study evaluating Itolizumab for Ulcerative Colitis - Medical Dialogues
Stocks to Watch, Feb 7: Biocon, SBI, LIC, M&M, Bharti Airtel, Ola Electric - Business Standard
Equillium Reports Positive Phase 2 Results for Itolizumab in Ulcerative Colitis, Shares Surge - Yahoo Finance
Equillium reports positive Phase 2 ulcerative colitis study data - MSN
Equillium reports positive Phase 2 ulcerative colitis study data By Investing.com - Investing.com South Africa
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis - Marketscreener.com
Phase 2 Clinical Success: New UC Treatment Achieves 23.3% Remission Rate, Rivaling Industry Standard - StockTitan
Lugman Group withdraws from purchase of “Industrial Park Fechenheim” - Yahoo Finance UK
Equillium Braces For Two Key Clinical Trial Data ReadoutsWill The Stock Get A Boost? - RTTNews
Equillium CFO Jason Keyes sells $6,500 in stock - MSN
Equillium CFO Jason Keyes sells $6,500 in stock By Investing.com - Investing.com Canada
Equillium stock touches 52-week low at $0.52 amid market challenges - MSN
Wall Street Analysts Predict a 75.79% Upside in Rigel (RIGL): Here's What You Should Know - MSN
Equillium (NASDAQ:EQ) Shares Down 0.9% – What’s Next? - Defense World
US Penny Stocks To Watch In January 2025 - Simply Wall St
Equillium (NASDAQ:EQ) Stock Price Down 1.6% – What’s Next? - Defense World
Equillium stock touches 52-week low at $0.6 amid market challenges - Investing.com Australia
Equillium Announces Board and Audit Committee Changes - TipRanks
Contrasting CSL (OTCMKTS:CSLLY) and Equillium (NASDAQ:EQ) - Defense World
Why Investors Shouldn't Be Surprised By Equillium, Inc.'s (NASDAQ:EQ) 35% Share Price Plunge - Simply Wall St
Equillium CFO Jason Keyes sells $7,000 in stock By Investing.com - Investing.com Nigeria
Equillium CFO Jason Keyes sells $7,000 in stock - Investing.com
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates - BioSpace
Equillium’s Q3 Financials and Clinical Progress in Focus - TipRanks
Equillium to Present at the Stifel Healthcare Conference - The Bakersfield Californian
Equillium to Present Clinical Pipeline Updates at Stifel Healthcare Conference | EQ Stock News - StockTitan
Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer - BioSpace
Opus Genetics, Inc. (IRD) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth - MSN
Equillium keeps equilibrium in GVHD after Ono no-go - BioWorld Online
Equillium says Ono not acquiring itolizumab, stock craters 36% - MSN
Ono says no to Equillium’s itolizumab - The Pharma Letter
Jones Trading Downgrades Equillium (EQ) - MSN
Equillium retains rights to itolizumab after Ono's option expires - Investing.com India
Equillium shares downgraded to hold from buy By Investing.com - Investing.com Canada
Equillium shares downgraded to hold from buy - Investing.com India
Equillium says Ono not acquiring itolizumab, stock craters 36% (NASDAQ:EQ) - Seeking Alpha
Equillium Maintains Rights to Itolizumab Following Ono Partnership - Business Wire
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):